Abstract 11P
Background
Despite recent advances in targeted therapies in acute myeloid leukemia (AML) there is still a high demand for highly specific targets to improve patient outcomes.
Methods
Kling Biotherapeutics employs a proprietary discovery platform, Kling-Select, to identify new therapeutic target-antibody pairs by interrogating the B cell repertoire of patients that have achieved remission via immune response.
Results
Here, we describe the discovery and characterization of anti-snRNP200 antibodies identified from three AML patients that have achieved complete response after allogeneic stem cell transplantation. We show that anti-snRNP200 specifically and selectively bind to AML cell lines that ectopically display snRNP200 on the outer cell surface.
Conclusions
This is surprising since snRNP200 is an RNA helicase normally present in the nucleus and therefore not expected to be exposed on the cell surface. These findings have been recently corroborated independently, showing that snRNP200 surface expression is limited to malignant cells and not expressed on normal hematopoietic stem cell progenitors (Knorr et al., 2023). We further explore the therapeutic potential of anti-snRNP200 with affinity matured variants produced with Kling-Evolve.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kling Biotherapeutics.
Funding
Kling Biotherapeutics.
Disclosure
S. Baumann, M. Kedde, B. Monica, K. Maijoor, M. Koslowski, S. Gullà: Financial Interests, Institutional, Full or part-time Employment: Kling Biotherapeutics. R. Schotte: Financial Interests, Personal, Full or part-time Employment: Kling Biotherapeutics.